2023
DOI: 10.1177/17588359231156382
|View full text |Cite
|
Sign up to set email alerts
|

A transcriptomics approach to expand therapeutic options and optimize clinical trials in oncology

Abstract: Background: The current model of clinical drug development in oncology displays major limitations due to a high attrition rate in patient enrollment in early phase trials and a high failure rate of drugs in phase III studies. Objective: Integrating transcriptomics for selection of patients has the potential to achieve enhanced speed and efficacy of precision oncology trials for any targeted therapies or immunotherapies. Methods: Relative gene expression level in the metastasis and normal organ-matched tissues … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
4

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(2 citation statements)
references
References 38 publications
0
2
0
Order By: Relevance
“…For instance, transcriptomic profiling, compared to DNA mutation-based approach, was reported to substantially extend the cohort of patients who could receive benefit from personalized molecular diagnostics, and prescription of the corresponding targeted therapies. This could increase median overall survival, as well as the speed and efficiency of clinical trials [67] , [68] , [69] .…”
Section: Resultsmentioning
confidence: 99%
“…For instance, transcriptomic profiling, compared to DNA mutation-based approach, was reported to substantially extend the cohort of patients who could receive benefit from personalized molecular diagnostics, and prescription of the corresponding targeted therapies. This could increase median overall survival, as well as the speed and efficiency of clinical trials [67] , [68] , [69] .…”
Section: Resultsmentioning
confidence: 99%
“…An objective response rate is the primary endpoint in both studies and preliminary results from subcohorts consisting of TGCT patients are eagerly awaited. Interestingly, preclinical evidence suggests an interplay and direct interaction between Nectin-4 and TIGIT as well as an upregulation of TIGIT and other immune-suppressive signals in metastatic compared to primary sites [69,70]. These observations could be applicable in TGCT biology as well and merit further investigation in the clinical setting.…”
Section: Emerging Immunotherapeutic Targetsmentioning
confidence: 94%